GLP-1 receptor binding
Semaglutide selectively binds to and activates the receptor targeted by native GLP-1.
Semaglutide
What current labeling and major human trials do—and do not—show
An approved medicine with several product-specific labels, not one interchangeable set of instructions
Semaglutide is a prescription GLP-1 receptor agonist available in multiple FDA-approved products. Indications, formulation, dosing instructions, warnings, and missed-dose directions differ by product, so this page separates label facts from trial findings and does not substitute for the product-specific Medication Guide or a prescriber.
Evidence audited · Sources and limitations shown beside each claim
Molecular identity
What the molecule actually is
- Classification
- Long-acting, modified GLP-1 analogue
- Chain
- 31 amino-acid residues plus a spacer and C18 fatty di-acid side chain
- Formula
- C187H291N45O59
- Molecular weight
- 4113.58 g/mol
Semaglutide is not simply native GLP-1 in a vial. The current FDA structural formula shows a modified peptide backbone plus a fatty-diacid side chain; that complete product-specific diagram is the reliable reference.
What the name alone cannot tell you
- Position 8 is modified to resist breakdown by DPP-4.
- Lysine at position 26 carries a spacer and C18 fatty di-acid that promotes albumin binding.
- Position 34 is modified so the fatty-diacid side chain attaches at one defined site.
Mechanism and certainty
How researchers think it works
FDA labeling establishes selective GLP-1 receptor agonism. The downstream effects differ by tissue and indication, and the label is explicit about what remains unknown.
Metabolic signaling
Label pharmacology describes glucose-dependent insulin secretion, reduced glucagon, and delayed gastric emptying.
Appetite regulation
GLP-1 signaling is involved in appetite and caloric-intake regulation; trial outcomes measure the result, not a personalized mechanism forecast.
Evidence boundary: The exact mechanism for cardiovascular-risk reduction and for MASH benefit has not been established. Gastric emptying alone should not be presented as the explanation for every outcome.
Product and regulatory distinctions
A compound name is not one interchangeable set of instructions. Product, formulation, indication, labeling, and jurisdiction matter.
Ozempic (injection)
FDA-approved prescription product for specified type 2 diabetes indications; consult the current label for the complete indication and limitations.
Current sourceWegovy (injection and tablets)
FDA-approved prescription products with formulation- and indication-specific labeling that includes chronic weight management, cardiovascular-risk reduction in a defined population, and accelerated approval for a defined noncirrhotic MASH population.
Current sourceRybelsus / Ozempic tablets
FDA-approved oral semaglutide products with product-specific administration and switching instructions in the current label.
Current sourceUse in the real world
How many people use semaglutide?
No authoritative semaglutide-only U.S. user count is publicly available.
A March 2026 KFF poll estimated that 12% of U.S. adults currently used some GLP-1 medicine. That is self-reported class-level use and includes semaglutide, tirzepatide, and other products; it cannot be relabeled as a semaglutide estimate.
Study results, visualized
What the measured results show
Semaglutide 2.4 mg−14.9%
Placebo−2.4%
Group averages from a randomized trial; not an individual forecast and not transferable to a different product.
Semaglutide6.5%
Placebo8.0%
Hazard ratio 0.80. The population had established cardiovascular disease; applicability is bounded by the trial criteria.
Claim-by-claim evidence map
Each finding is tied to the population and product actually studied. Trial results are not personal predictions.
Semaglutide 2.4 mg was studied for chronic weight management in adults without diabetes.
- Population
- 1,961 adults with overweight or obesity and without diabetes in STEP 1.
- Finding
- At 68 weeks, the semaglutide group had a larger mean body-weight reduction than placebo alongside lifestyle intervention.
- Limits
- Trial eligibility, structured follow-up, discontinuation, adverse events, and the studied product/dose limit how results apply to an individual. This is not a personal outcome forecast.
Semaglutide 2.4 mg reduced major cardiovascular events in the SELECT trial population.
- Population
- 17,604 adults aged 45 or older with established cardiovascular disease and overweight or obesity, without diabetes.
- Finding
- A primary cardiovascular endpoint occurred in 6.5% of the semaglutide group and 8.0% of the placebo group (hazard ratio 0.80).
- Limits
- The finding applies to the SELECT eligibility criteria and should not be generalized to people without established cardiovascular disease or to unstudied formulations.
Semaglutide has an elimination half-life of approximately one week.
- Population
- Pharmacokinetic information from FDA-reviewed product labeling.
- Finding
- The long half-life supports product-specific weekly dosing and a prolonged washout period.
- Limits
- A population half-life is not a personalized concentration forecast and must not be used to change dose timing without the prescriber and product instructions.
What this evidence does not answer
- Trial averages cannot predict an individual's benefit, tolerability, or treatment duration.
- Evidence for one branded formulation, dose, indication, or population should not be transferred automatically to compounded or otherwise different products.
- Online claims about dose splitting, non-label combinations, or self-directed titration are not established by the sources summarized here.
Useful information to organize between visits
- The product name and prescribed formulation—not only the word semaglutide
- Dose date and time exactly as taken
- Injection location when applicable, so the same spot is not reused repeatedly
- Symptoms with onset, severity, duration, and whether they affected eating or hydration
- Questions, missed doses, or administration problems to discuss with the prescriber or pharmacist
Questions to bring to a clinician or pharmacist
- 1.Which product-specific Medication Guide and instructions apply to me?
- 2.What symptoms or changes should prompt a call, urgent evaluation, or a treatment review?
- 3.How should my other medicines and relevant health conditions affect monitoring?
- 4.What should I do if a dose is late or missed under my specific product instructions?
How to use this research profile
This page aggregates regulatory documents and published human research. Its claims, citations, populations, and limitations received an independent editorial evidence check. Last editorial audit: . It has not been medically reviewed by a clinician. It provides general education, not diagnosis, treatment, dosing instructions, or advice for an individual. Use the product-specific official information and consult a qualified clinician or pharmacist for personal decisions.
Primary sources
- Ozempic prescribing informationU.S. Food and Drug Administration · Published 2025 · Accessed July 12, 2026
- Wegovy prescribing informationU.S. Food and Drug Administration · Published 2026-03 · Accessed July 13, 2026
- Wegovy prescribing informationU.S. Food and Drug Administration · Published 2025 · Accessed July 12, 2026
- Rybelsus and Ozempic tablets prescribing informationU.S. Food and Drug Administration · Published 2026 · Accessed July 12, 2026
- KFF Health Tracking Poll: GLP-1 UseKFF · Published 2026-03 · Accessed July 13, 2026
- Once-Weekly Semaglutide in Adults with Overweight or ObesityThe New England Journal of Medicine via PubMed · Published 2021 · Accessed July 12, 2026
- Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesThe New England Journal of Medicine via PubMed · Published 2023 · Accessed July 12, 2026
Turn scattered notes into a useful treatment history
Dosi organizes timing, locations, symptoms, reminders, and questions for your next appointment. It does not prescribe or replace your care team.
Start tracking free